RNS Hotlist with Zak Mir: CGNR, PREM, GDR & KDR

This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.

Author @ZaksTradersCafe

Conroy Gold and Natural Resources (CGNR), the gold exploration and development company, announced that it has acquired an equity interest in AIM-quoted Karelian Diamond Resources (KDR) through entering into a debt capitalisation arrangement, including the issue of convertible loan notes, with Karelian Diamonds. Following the Investment and completion of the fundraising by Karelian Diamonds, Conroy Gold is expected to be interested in 5,000,000 KDR Shares equivalent to 5.29% of the enlarged issued share capital of Karelian Diamonds.

Comment: It may be said that the pairing up of Conroy and Karelian appears at first glance to be almost as unexpected as that between Bing Crosby and David Bowie. It is noteworthy that there is no quote regarding the deal in the RNS to explain the move.

Premier African Minerals (PREM) announced, after receiving further institutional interest following the funding announced 15 May 2023, a further placing to raise £610,000 before expenses at an issue price of 0.925 pence per new ordinary share for the ongoing Zulu Lithium and Tantalum Project Pilot Plant optimisation. George Roach, Chief Executive Officer, has agreed to participate in the placing at the Placing Price by way of a subscription of £110,000.

Comment: PREM takes advantage of the bull run in its stock, with a raise of just over £600,000. It is noteworthy that the CEO has led from the front, although given the ongoing interest in the stock, the company could have raised far more.

Genedrive (GDR), the point of care molecular diagnostics company, announced that the UK’s National Institute for Health and Care Excellence has recommended in draft guidance that CYP2C19 genotyping should be used before clopidogrel administration in the management of ischemic stroke patients. GDR said it remains focused on achieving release and UKCA approval of the Genedrive CYP2C19 ID Kit in advance of the final NICE guidance publication date.

Comment: It has generally been difficult for many companies that benefitted from the pandemic bubble to emerge successfully as conditions normalised. However, Genedrive continues to finesse its offering as the latest news from NICE underlines.

Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.